Abstract:
Introduction: WHO notes that diabetes mellitus (DM) leads to increased mortality of patients by 2-3
times and reduces their life duration by 10-30 %. Epidemiological studies in Ukraine indicate a permanent increase in the number of patients with both DM types. The most objective and long-term indicator
of diabetes compensation is glycated hemoglobin (HbAlc).
Purpose: Our study was to estimate the stage of compensation for patients with DM types 1 and 2 in
Ternopil region on the basis of HbAlc levels.
Materials and methods: We examined 285 patients with type 2 diabetes, among them 150 people
received insulin therapy. The duration of diabetes was from 2 to 17 years. Patients’ age was from 42 to 75
years. Due to the fact that the study involved 49.2% of patients older than 50 years, stages of compensation of diabetes were the following: HbAlc less than 7.0% - good control, 7,0-8,0% - satisfactory control,
above 8.0% - poor control.
Results: The amount of patients with HbAlc level under 7% was 8.65%, with HbAlc from 7.0 to
8.0% - 17.11%, with HbAlc above 8.0% - 74.24%, respectively. The average HbAlc level among clients
with type 2 diabetes and insulin treatment was (9.62±0.07)% and among those, who used anti-diabetic
drugs - (9.34±0.08)%, respectively.
The average HbAlc concentration in patients with type 2 DM in Ternopil region, Ukraine in 2011
was (9.48±0.06)%.
Conclusions: The average level of glycated hemoglobin in patients with type 2 diabetes mellitus in
Ternopil region, Ukraine in 2011 was (9.48±0.06)%, and did not depend on the method of its treatment
(insulin or anti-diabetic drugs). The majority of clients with diabetes mellitus type 2 (74.24%) presented
poor control of the disease.
